http://weekly.chinacdc.cn/ China CDC Weekly cdcwjournal@163.com cdcwjournal@163.com en cdcwjournal@163.com 2096-7071 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.149?pageType=en Zundong Yin China CDC Weekly. 2020 2(30): 557-558. Zundong Yin China CDC Weekly. 2020 2(30): 557-558. The 10<sup<th</sup< World Hepatitis Day 2020 — July 28, 2020 Zundong Yin 2020-07-24 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(30): 557-558. article doi:10.46234/ccdcw2020.149 10.46234/ccdcw2020.149 China CDC Weekly 2 30 2020-07-24 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.149?pageType=en 557 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.150?pageType=en Ning Miao, Hui Zheng, Xiaojin Sun, Fuzhen Wang, Guomin Zhang, Zundong Yin China CDC Weekly. 2020 2(30): 559-563. Ning Miao, Hui Zheng, Xiaojin Sun, Fuzhen Wang, Guomin Zhang, Zundong Yin China CDC Weekly. 2020 2(30): 559-563. Acute Hepatitis B — China, 2005−2019 Ning Miao, Hui Zheng, Xiaojin Sun, Fuzhen Wang, Guomin Zhang, Zundong Yin 2020-07-24 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(30): 559-563. article doi:10.46234/ccdcw2020.150 10.46234/ccdcw2020.150 China CDC Weekly 2 30 2020-07-24 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.150?pageType=en 559 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.151?pageType=en Wenzhan Jing, Jue Liu, Min Liu <sec< <b< <b<What is already known on this topic?</b< </b< <p<The global prevalence of hepatitis C virus (HCV) infection in 2015 has been modeled to assess the disease burden in 21 Global Burden of Disease (GBD) regions. However, there is no study to clarify the global long-term trends and regional differences in HCV infection prevalence.</p< </sec< <sec< <b< <b<What is added by this report?</b< </b< <p<This report clarified the global temporal trends and regional differences in HCV infection prevalence. Global HCV infection age-standardized prevalence rate (ASR) gradually decreased from 1990 to 2017 except in Eastern Europe, and liver cancer due to hepatitis C ASR increased worldwide with drastic shifts in low-middle Socio-Demographic Index (SDI) regions in the last decade.</p< </sec< <sec< <b< <b<What are the implications for public health practice?</b< </b< <p<HCV is still prevalent worldwide despite the development of highly effective direct-acting antivirals (DAAs) and showed a reemergence concurrent with the opioid crisis. HCV infection prevention might involve at least 3 aspects: first, prohibiting HCV widespread transmission among general populations; second, increasing global DAAs coverage; and third, continuously investing in the development of the HCV vaccine.</p< </sec< China CDC Weekly. 2020 2(30): 564-569. Wenzhan Jing, Jue Liu, Min Liu <sec< <b< <b<What is already known on this topic?</b< </b< <p<The global prevalence of hepatitis C virus (HCV) infection in 2015 has been modeled to assess the disease burden in 21 Global Burden of Disease (GBD) regions. However, there is no study to clarify the global long-term trends and regional differences in HCV infection prevalence.</p< </sec< <sec< <b< <b<What is added by this report?</b< </b< <p<This report clarified the global temporal trends and regional differences in HCV infection prevalence. Global HCV infection age-standardized prevalence rate (ASR) gradually decreased from 1990 to 2017 except in Eastern Europe, and liver cancer due to hepatitis C ASR increased worldwide with drastic shifts in low-middle Socio-Demographic Index (SDI) regions in the last decade.</p< </sec< <sec< <b< <b<What are the implications for public health practice?</b< </b< <p<HCV is still prevalent worldwide despite the development of highly effective direct-acting antivirals (DAAs) and showed a reemergence concurrent with the opioid crisis. HCV infection prevention might involve at least 3 aspects: first, prohibiting HCV widespread transmission among general populations; second, increasing global DAAs coverage; and third, continuously investing in the development of the HCV vaccine.</p< </sec< China CDC Weekly. 2020 2(30): 564-569. Global Trends and Regional Differences in Hepatitis C Virus Infection Prevalence and Implications for Prevention — Worldwide, 1990−2017 Wenzhan Jing, Jue Liu, Min Liu 2020-07-24 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(30): 564-569. article doi:10.46234/ccdcw2020.151 10.46234/ccdcw2020.151 China CDC Weekly 2 30 2020-07-24 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.151?pageType=en 564 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.152?pageType=en Jing Sun, Yuanqiu Li, Xing Fang, Yan Wang, Yinan Han, Yang Liu, Jingyuan Cao, Wenting Zhou, Hui Zheng, Wenqing Yao <sec< <p< <b<What is already known about this topic?</b< </p<</sec<<sec< <p<Hepatitis A (HA) is caused by acute hepatitis A virus (HAV) infection and was once very common in China. Following the 2008 introduction of the HA vaccine into the national Expanded Program on Immunization (EPI), the incidence of reported HA in China decreased markedly. However, HA epidemics still occur in Liaoning Province every 3–5 years, although with far fewer cases than in the pre-HA-vaccination era.</p<</sec<<sec< <p< <b<What is added by this report?</b< </p<</sec<<sec< <p<Between January 1, 2020 and March 18, 2020, the number of reported cases of HA in Dalian and Dandong cities of Liaoning Province increased significantly compared with the same period in previous years. All cases were sporadic, and cases were seen in nearly every township. The increase in HA occurred one month after local fresh seafood became available with most cases being among adults. A case-control study showed that consuming raw or undercooked seafood, clams, snapping shrimp, and oysters were significantly associated with the increase in HA.</p<</sec<<sec< <p< <b<What are the implications for public health practices?</b< </p<</sec<<sec< <p<Strengthening health education for residents to avoid consumption of raw seafood and encouraging HAV vaccination of adults aged 20 to 54 years are important to prevent periodic HAV endemic outbreaks. Further multisectoral cooperation must be emphasized on HA surveillance in areas with a high prevalence of HA.</p<</sec< China CDC Weekly. 2020 2(30): 570-574. Jing Sun, Yuanqiu Li, Xing Fang, Yan Wang, Yinan Han, Yang Liu, Jingyuan Cao, Wenting Zhou, Hui Zheng, Wenqing Yao <sec< <p< <b<What is already known about this topic?</b< </p<</sec<<sec< <p<Hepatitis A (HA) is caused by acute hepatitis A virus (HAV) infection and was once very common in China. Following the 2008 introduction of the HA vaccine into the national Expanded Program on Immunization (EPI), the incidence of reported HA in China decreased markedly. However, HA epidemics still occur in Liaoning Province every 3–5 years, although with far fewer cases than in the pre-HA-vaccination era.</p<</sec<<sec< <p< <b<What is added by this report?</b< </p<</sec<<sec< <p<Between January 1, 2020 and March 18, 2020, the number of reported cases of HA in Dalian and Dandong cities of Liaoning Province increased significantly compared with the same period in previous years. All cases were sporadic, and cases were seen in nearly every township. The increase in HA occurred one month after local fresh seafood became available with most cases being among adults. A case-control study showed that consuming raw or undercooked seafood, clams, snapping shrimp, and oysters were significantly associated with the increase in HA.</p<</sec<<sec< <p< <b<What are the implications for public health practices?</b< </p<</sec<<sec< <p<Strengthening health education for residents to avoid consumption of raw seafood and encouraging HAV vaccination of adults aged 20 to 54 years are important to prevent periodic HAV endemic outbreaks. Further multisectoral cooperation must be emphasized on HA surveillance in areas with a high prevalence of HA.</p<</sec< China CDC Weekly. 2020 2(30): 570-574. An Epidemic of Hepatitis A — Liaoning Province, 2020 Jing Sun, Yuanqiu Li, Xing Fang, Yan Wang, Yinan Han, Yang Liu, Jingyuan Cao, Wenting Zhou, Hui Zheng, Wenqing Yao 2020-07-24 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(30): 570-574. article doi:10.46234/ccdcw2020.152 10.46234/ccdcw2020.152 China CDC Weekly 2 30 2020-07-24 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.152?pageType=en 570 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.153?pageType=en Lance E. Rodewald China CDC Weekly. 2020 2(30): 575-576. Lance E. Rodewald China CDC Weekly. 2020 2(30): 575-576. Exporting China’s Successes in Vaccine Preventable Hepatitis Lance E. Rodewald 2020-07-24 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(30): 575-576. article doi:10.46234/ccdcw2020.153 10.46234/ccdcw2020.153 China CDC Weekly 2 30 2020-07-24 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.153?pageType=en 575 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.154?pageType=en Peter Hao, Ying Zhang, Zhenjun Li, Jingjing Xi, Feng Tan China CDC Weekly. 2020 2(30): 577-578. Peter Hao, Ying Zhang, Zhenjun Li, Jingjing Xi, Feng Tan China CDC Weekly. 2020 2(30): 577-578. Huaqing Wang, China CDC’s Chief Expert in National Immunization Program Peter Hao, Ying Zhang, Zhenjun Li, Jingjing Xi, Feng Tan 2020-07-24 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(30): 577-578. article doi:10.46234/ccdcw2020.154 10.46234/ccdcw2020.154 China CDC Weekly 2 30 2020-07-24 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.154?pageType=en 577

map